{
  "@context": "https://orbyd.app/schemas/dossier.v1.json",
  "ticker": "WGS",
  "name": "GeneDx Holdings Corp.",
  "url": "https://orbyd.app/dossiers/WGS/",
  "json_url": "https://orbyd.app/dossiers/WGS.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "graded_conviction": "LOW",
  "archetype": {
    "code": "a5",
    "n": 5
  },
  "current_thesis": "Busted-growth genomics name; the recovery off the −49% May guide-cut crash has stalled in the low-$60s, below the $74.83 200-day. The confirmed Aug 3 Q2 print (blended ARR vs the ~$3,300 baseline) is the binary — the same day as the class-action lead-plaintiff deadline. Mean-reversion into an event, not a fresh accelerating leg; stand aside into the print.",
  "invalidation_trigger": "A weekly close below $52 breaks the June recovery shelf and the rising 50-day near $56.56, reopening the path to the $32.21 May low; a Q2 blended ARR (Aug 3) below ~$3,300 confirms the busted-growth regime.",
  "catalyst_date": "2026-08-03",
  "outcome": "PLAYED_OUT",
  "outcome_date": "2026-08-04",
  "invalidation_fired": false,
  "themes": [
    "medtech-diagnostics",
    "precision-biotech-therapeutics"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Long-term optionality is GUARDIAN newborn genome screening (JAMA; NY DOH + Illumina, 100k target) but payer reimbursement is 'years' away per Freedom Capital — not a near-term driver.",
    "Q2 2026 print CONFIRMED Monday Aug 3 2026 after close (call 4:30pm ET) — key metric blended ARR vs ~$3,300 Q1 baseline (2025 was $3,750); expect earnings/quiet-period blackout the trading days before.",
    "Aug 3 2026 is a double event: Q2 print AND Hagens Berman securities class-action lead-plaintiff deadline (class period Apr 16 2025 – May 4 2026) — concurrent legal/headline risk.",
    "Busted-momentum classification: −49% on May 5 2026 on a 12% FY guide cut ($540–555M → $475–490M). Recovery ran $32.21 low → ~$67.51 (Jul 2) → $63.25 (Jul 23), rounding over below the $74.83 200-day. Treat as mean-reversion until ARR stabilizes and a higher-low base holds above the 50-day.",
    "Analyst re-rating: TD Cowen $85 from $55 (Jul 10, Buy), BTIG Buy reiterated (Jul 15); consensus avg ~$82, high $100, low $63, 9 buys / 0 sells. Prior cuts: Freedom Capital $93 (from $177), Wells Fargo $75 (from $155).",
    "Demand intact (E/G volume +34% YoY, 27,488 tests Q1; adj GM 69%); broken leg is pricing/reimbursement (genome mix shift, ARR ~half of exome, zero-pays), not adoption.",
    "Overhang: $31.2M Fabric Genomics impairment (~94% of $33.2M cost) = capital-allocation/credibility tax on the multiple.",
    "GUARDIAN newborn-screening (NY DOH + Illumina, 100k target) is long-dated optionality — payer reimbursement 'years' away per Freedom Capital, not a near-term driver."
  ],
  "body_markdown": "## Current Thesis\nThe precision-genomics narrative that carried WGS to $170.87 broke on the May 4, 2026 Q1 print and has not been repaired — it has only been retraced. Management cut FY2026 revenue guidance 12% (from $540–555M to $475–490M), stepped exome/genome growth down from a 33–35% pace to \"at least 20%,\" and blended average reimbursement rate (ARR) landed near $3,300, roughly $200 under plan and down from $3,750 in 2025. Shares fell −49% on May 5 and then staged a persistent retrace from the $32.21 low to $59.92 (June 12), extending to a July high near $67.51 (July 2) before fading to $63.25 (July 23). That advance has rounded over in the low-$60s, still below the $74.83 200-day. The event that defines the thesis — pricing/reimbursement — is not re-tested until the confirmed August 3 Q2 print, which falls on the same day as the securities class-action lead-plaintiff deadline. This is a mean-reversion bounce stalling into a binary, so a fresh entry here pays low-$60s for a busted-growth name days before the number that broke it prints again.\n\n## Bull Case\n- Demand is intact: exome/genome volume +34% YoY to 27,488 tests in Q1 (reported May 4, 2026); FY26 still guides ≥20% E/G volume growth. The break is in downstream realization, not adoption.\n- Adjusted gross margin held 69% in Q1 2026 despite the revenue miss — the unit economics survived the guide cut.\n- Sell-side keeps re-rating the recovery: TD Cowen raised its target to $85 from $55 (July 10, Buy), BTIG reiterated Buy (July 15), and the consensus average sits near $82 (high $100) with 9 buys and 0 sells.\n- Management refresh: Mark Gardner appointed President effective June 15 (announced June 16), a governance signal after the impairment and guide-cut credibility hit.\n- Long-dated optionality from the GUARDIAN newborn-screening study (JAMA-published; NY State DOH + Illumina, 100,000-newborn target): among the first ~4,000 enrolled, 3% carried serious conditions, 92% off standard panels — a large TAM if genome-as-first-line screening earns payer coverage.\n- Price still holds above the rising 50-day MA ($56.56), so the recovery structure off the $32.21 low is technically intact heading into the print.\n\n## Bear Case\n- Guidance credibility took structural damage: FY26 revenue cut 12% eleven weeks after the February frame, with E/G growth stepped down to \"at least 20%\" — a regime shift, not a rounding error.\n- Reimbursement weakness is mechanical and durable: the ARR miss came from mix shift toward genome, whose ARR runs roughly half of exome, with more zero-pays as outpatient genome coverage lags. Freedom Capital cut its target to $93 from $177 and flagged improved outpatient genome reimbursement as potentially \"years\" away.\n- Q1 2026 (May 4) missed on both lines: EPS −$0.28 vs −$0.01 consensus; revenue $102.3M vs ~$112.45M expected; GAAP net loss $63.3M, roughly 10x the year-ago quarter.\n- Litigation sits directly on the print: the Hagens Berman securities class action (class period April 16, 2025 – May 4, 2026) carries an August 3, 2026 lead-plaintiff deadline — the same day as the Q2 report.\n- The $31.2M Fabric Genomics impairment (~94% of the $33.2M cost written off in ~12 months) is a capital-allocation black eye compounding the credibility hit.\n- Price ($63.25, July 23) trades below the $74.83 200-day; moving-average signals read net bearish (3 buy / 9 sell). The stock has nearly doubled off the low into no fresh fundamental catalyst, and TD Cowen's $85 / the ~$82 consensus leave only ~30% headroom into a binary whose low estimate is $63. Short interest grew into mid-July.\n\n## Setup & Price Structure\nLast reference $63.25 (July 23, 2026), off the July high near $67.51 (July 2) and below the $74.83 200-day; the 50-day sits at $56.56 and is rising. The 52-week range is $32.21–$170.87. The recovery path reads $32.21 (May 5) → $59.92 (June 12) → ~$67.51 (July 2) → $63.25 (July 23) — an orderly retrace that has rounded over and lost momentum in the low-$60s. Price is wedged between the rising 50-day and the falling 200-day, which makes the low-$60s a decision zone rather than a base breakout, and the resolution is scheduled: the August 3 print. Extension is absent, but so is a fresh catalyst — the tape is coiling into an event, not accelerating away from one.\n\n## Catalyst Calendar (next 30 days)\n\n*No upcoming dated catalysts on file — the dated entries below have passed.*\n\n## Elapsed catalysts\n\n- 2026-08-03 (confirmed): Q2 2026 financial results after the close, conference call 4:30 p.m. ET. The gradeable metric is blended ARR versus the ~$3,300 Q1 baseline (2025 ran $3,750), plus whether the ≥20% E/G volume trajectory holds. Expect an earnings/quiet-period blackout the trading days prior. *(passed 6d ago)*\n- 2026-08-03: Hagens Berman lead-plaintiff deadline (class period April 16, 2025 – May 4, 2026) — headline/legal risk landing concurrent with the print. *(passed 6d ago)*\n\n## What Would Change Our Mind\nA weekly close below $52 breaks the June recovery shelf and the rising 50-day near $56.56, reopening the path toward the $32.21 May low and confirming the retrace was a dead-cat rather than a base. On the fundamental side, a Q2 blended ARR below ~$3,300 on August 3 confirms the busted-growth regime and validates the reimbursement bear case. The bull repair runs the other way: an ARR re-acceleration back toward $3,750 with a reaffirmed or raised FY guide would mend the broken pricing leg, and a reclaim of the $74.83 200-day on volume would turn the low-$60s stall into a genuine trend recovery worth pressing.\n\n## Correlation Notes\nWGS trades as a rate-sensitive, unprofitable small-cap genomics name — it moves with biotech risk appetite (XBI) and rate expectations more than with the broad tape. Illumina (ILMN) is the closest read-through: it is both the sequencing supplier and the GUARDIAN newborn-screening partner, so ILMN commentary on genome demand is a leading tell. Diagnostics peers Natera (NTRA), Exact Sciences (EXAS) and the tools complex (TMO) frame sentiment on reimbursement-driven diagnostics. The dominant driver, however, is idiosyncratic and non-macro: CMS/commercial payer coverage of outpatient genome sequencing determines ARR, and no index hedge tracks that.",
  "first_seen": "2026-06-05",
  "last_analyzed": "2026-07-25T08:04:19+00:00",
  "last_synthesized": "2026-07-25",
  "last_update_source": "watchlist_research",
  "license": "Content © orbyd. Cite the canonical URL."
}